VYNE Therapeutics Inc.
VYNE
$0.37
-$0.01-2.69%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -65.15% | 106.12% | 10.53% | 6.14% | 46.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -65.15% | 106.12% | 10.53% | 6.14% | 46.67% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -65.15% | 106.12% | 10.53% | 6.14% | 46.67% |
| SG&A Expenses | -16.97% | -13.13% | -18.40% | -2.18% | 2.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.16% | 25.69% | 86.07% | 108.13% | 1.35% |
| Operating Income | 27.45% | -24.62% | -86.91% | -109.99% | -0.76% |
| Income Before Tax | 38.83% | -37.85% | -95.22% | -100.25% | 6.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 38.83% | -37.85% | -95.29% | -100.25% | 6.41% |
| Earnings from Discontinued Operations | 27.27% | 0.00% | 77.78% | -- | 45.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.82% | -37.80% | -94.28% | -84.64% | 6.48% |
| EBIT | 27.45% | -24.62% | -86.91% | -109.99% | -0.76% |
| EBITDA | -- | -- | -87.39% | -- | -- |
| EPS Basic | 39.07% | -37.47% | -39.29% | 85.77% | 92.81% |
| Normalized Basic EPS | 25.31% | -37.55% | -43.37% | 84.57% | 92.80% |
| EPS Diluted | 39.07% | -37.47% | -39.29% | 85.77% | 92.81% |
| Normalized Diluted EPS | 25.31% | -37.55% | -43.37% | 84.57% | 92.80% |
| Average Basic Shares Outstanding | 0.41% | 0.22% | 36.18% | 1,197.59% | 1,200.73% |
| Average Diluted Shares Outstanding | 0.41% | 0.22% | 36.18% | 1,197.59% | 1,200.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |